JPH104918A - Nutriment composition containing nucleic acid related compound - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a nutriment composition containing a nucleic acid related compound, having an increasing action of a lipid, a protein, a cholesterol and a nucleic acid at a biomembrane and capable of promoting growth in a weanling state by including a nucleic acid, DHA (docosahexaenoic acid), arachidonic acid and a cholesterol as an active ingredient. SOLUTION: This nutriment composition containing a nucleic acid related compound includes one or more kinds of nucleic acids selected from a nucleotide, a nucleoside, a nucleic acid (DNA or RNA) and a base which is a constituent thereof, DHA, arachidonic acid and a cholesterol. Moreover, the nutriment composition is obtained, for example, by blending 5-10mg cytidine monophosphate, 2-4mg uridine monophosphate, 0-4mg adenosine monophosphate, 1-3mg guanosine monophosphate and/or 2-4mg inosine monophosphate based on 100g powder with a eatable oil and fat such as a fish oil containg 4.9-60mg arachidonic acid, 24.5-250mg DHA and 56-90mg cholesterol based on 100g powder.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a nutritional composition, and more particularly, to a nutritional composition containing a nucleic acid-related substance having an action of improving various biological components in a biological membrane.

[0002]

2. Description of the Related Art Docosahexaenoic acid (DHA) is an n-
It is a series of polyunsaturated fatty acids and contains 0.63 ± 0.24% as fatty acid composition in Japanese breast milk (Yonekubo et al., Child Health Research, 46, 349 (1987)). Plays an important role in their development as lipid components in the infant brain and retina (Kanazawa et al .: Lipids 1991; 26; 5
3-57). And, in view of such importance, formula powder with enhanced DHA is actually commercially available.

[0003] On the other hand, in view of the effects on animal growth and skin, it has been conventionally considered that the essential fatty acid is only linoleic acid, which is an n-6 series polyunsaturated fatty acid. It has been recognized that it is an essential fatty acid for living organisms because of its growth promotion effect in relation to neonatal growth, its role as eicosanoid in the living body, or its structural function in membrane lipids (Crawford et al., Th.
e role of Rats in Human Nutrition; edited by Vergr
osssen and Crawford, Academic Press, 1989). However, at present, infant formula containing arachidonic acid fortified is not commercially available.

[0004] With regard to this arachidonic acid, D
DHA levels in erythrocyte membrane phospholipids of low-birth-weight infants bred with infant formulas fortified with HA in the form of fish oil are similar to those of breast-fed infants, but arachidonic acid levels tend to be lower than those of breast-fed infants. It has been pointed out (Omoto: Japanese Society of Pediatrics 1990; 94; 224-234). Also, in fish oil and cholesterol enriched systems, reduced arachidonic acid content in plasma and tissues has been observed (Garg et al .; Lipid
s 1989; 24, 226-270).

Thus, arachidonic acid, DHA and / or
It is the current state of the art that there is no known example of successful simultaneous enhancement of cholesterol.

[0006]

DISCLOSURE OF THE INVENTION The present invention has been made in view of the above-mentioned state of the art. In the neonatal period, n-3 series and n-6 series polyunsaturated fatty acids are converted into plasma. It is necessary to strengthen the inside, and the balance, that is, the ratio of n-3 series / n-6 series fatty acids (the ratio of ω-3 polyunsaturated fatty acids / ω-6 polyunsaturated fatty acids) is also important. The present inventors have further studied this point,
We recognized for the first time the importance not only in plasma but also in biological membranes such as erythrocyte membranes, and set the technical task to increase DHA and arachidonic acid in erythrocyte membranes in a well-balanced manner.

[0007]

SUMMARY OF THE INVENTION The present invention has been made for the purpose of solving the above technical problems, and as a result of various studies, it has been found that fish oil containing DHA and arachidonic acid and fats and oils containing cholesterol contain: Furthermore, it has been found for the first time that a food containing a fortified nucleotide increases polyunsaturated fatty acids (n-3 and n-6) and monounsaturated fatty acids in PC and PE of erythrocyte membrane.

The present inventors have further studied based on this useful new finding. As a result of enhancing nucleic acid / DHA / arachidonic acid / cholesterol, the present inventors have found that in addition to erythrocyte membranes, biological membranes such as small intestinal mucosa and liver biological membranes can be obtained. , Unsaturated fatty acids and choline-containing phospholipids, lipids and proteins such as PC and PE,
The inventors have obtained a conventionally unknown useful new finding that useful biological substances such as cholesterol (sometimes referred to as Ch) and DNA increase, and have finally completed the present invention.

That is, the present invention has an effect of increasing lipids, proteins, cholesterol and / or nucleic acids in a biological membrane characterized by containing nucleic acids, DHA, arachidonic acid (also referred to as AA) and cholesterol as active ingredients. The nutritional composition is a basic technical idea. Hereinafter, the present invention will be described specifically.

[0010]

BEST MODE FOR CARRYING OUT THE INVENTION The nutritional composition according to the present invention contains nucleic acid / DHA / arachidonic acid / cholesterol as an active ingredient. Examples of the nucleic acid include nucleotides, nucleosides, nucleic acids (RNA, DNA), and the like. One or more bases as constituent components are used as appropriate.

(1) The bases mentioned here are adenine, guanine, hypoxanthine, xanthine, cytosine, uracil, and thymine. (2) The nucleosides referred to herein are uridine, adenosine, guanosine, cytidine, ribothymidine, deoxyadenosine, deoxyguanosine, deoxyuridine, deoxycytidine, thymidine, inosine, and xanthosine. (3) The nucleotide herein refers to a compound in which phosphoric acid is bonded to a sugar moiety of a nucleoside by an ester bond. The position of the phosphate to be bonded may be anywhere, and the number of bonded phosphates may be any number. Further, for example, a compound in which one phosphate binds at both the 5 ′ and 3 ′ positions is also included in the nucleotide. Also in this case, the number and position of the phosphate to be bound may be anywhere. (4) The nucleic acid referred to here is a polynucleotide such as DNA or RNA or a polynucleotide to which the nucleotide of (3) is bound. In the following, the present invention will be specifically described using a nucleotide as an example of the nucleic acid.

To prepare the nutritional composition according to the present invention,
It is necessary to enhance the required amount of each active ingredient, but the active ingredient can be used not only in a purified form but also in a composition or contained form. Various processed products such as solids, liquids, suspensions, and diluents can also be used. To prepare the composition according to the present invention, each active ingredient may be blended in a required amount, or a substance containing the active ingredient may be used.

As the active ingredient-containing substance, edible oils and fats are exemplified, and the composition according to the present invention can be prepared by adding nucleotides thereto. As edible oils and fats, all liquid, semi-solid and solid oils and fats derived from animals and plants can be used, and oils and fats subjected to various treatments such as hydrogenation treatment, molecular distillation treatment, and fractionation treatment can also be used. Non-limiting examples of edible oils and fats include the following: fish oil, tallow, lard, milk, sheep, horse oil, liver oil, egg oil, soybean oil, corn oil, palm oil, palm kernel oil, palm Oil, rice oil, rapeseed oil, cottonseed oil, perilla oil, sesame oil, safflower oil,
Peanut oil and the like.

[0014] Any of these edible oils and fats can be used in the present invention, but fish oil having a high DHA and cholesterol content is one example of a particularly suitable edible oil and fat. The fish oil used in the present invention may be a commonly used fish oil, for example, tuna oil, bonito oil, sardine oil, mackerel oil, saury oil, walleye pollack oil and the like are used, and also a mixed oil or a concentrated oil thereof. Tuna oil and bonito oil having a high DHA content are preferred for infant formula.

One or more of such edible fats and oils are used together with nucleotides. As edible fats and oils, DHA, cholesterol, fats and oils with a high arachidonic acid content are suitable, but when there is no fat or oil rich in all of them, one or two fats with a high content of each component are selected, These may be used in combination. If necessary, the edible oils and fats may be subjected to treatments such as concentration, molecular distillation, and fractionation to increase the content of each component, and the edible oils and fats thus treated may be used.

[0016] For example, molecular fats and oils such as fish oils are subjected to molecular distillation and fractionation according to a conventional method to increase the DHA concentration, and to concentrate cholesterol in fish oils using a supercritical gas such as carbon dioxide ( JP-A-61-261398
Publication), and it is of course possible to directly add each component to strengthen the fats and oils. In this case, each component may directly add a purified product, or in the case of arachidonic acid, may use the content of each component such as using soybean lecithin.

The content of each of these components in the edible oil / fat is 4.9 to 60 m / arachidonic acid per 100 g of powder.
g, DHA 24.5-250 mg, cholesterol 5
It is good to be 6 to 90 mg. The content can be appropriately adjusted by controlling the amount added, the original content in the used fats and oils, the conditions of the concentration treatment, and the like.

Such edible oils and fats are blended together with nucleotides, and the nucleotides include cytidine-monophosphate (CMP), uridine-monophosphate (UMP),
A nucleotide mixture comprising one or more of adenosine-monophosphate (AMP), guanosine-monophosphate (GMP), and inosine-monophosphate (IMP) is used. Of course, each nucleotide may be individually blended in a required amount. The compounding amount is CMP 5 to 100 g of powder.
10 mg, UMP 2-4 mg, AMP 0-4 mg.
It is preferable to use 1 to 3 mg of GMP and / or 2 to 4 mg of IMP.

The edible oils and nucleotides prepared as described above can be mixed with various drinks and foods to freely produce a food and drink type nutritional composition including infant foods. The nutritional composition (including beverages) according to the present invention has no problem in flavor, texture, appearance, etc., and is in various forms such as baby food, healthy food, healthy drink, in addition to dairy products such as milk formula. It can be advantageously used as food and drink for not only infants, but also adults, healthy persons, sick people, elderly people and the like.

In order to prepare a milk preparation as the baby food according to the present invention, for example, the following may be performed. That is, after skim milk, milk casein, milk desalted whey protein, lactose, oligosaccharide, sucrose and dextrin are dissolved and mixed in warm water, vitamins and minerals (for example, vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , vitamin B ₆₎ B ₁₂ , L
-Sodium ascorbate, calcium pantothenate, niacin, folic acid, sodium ferrous citrate, ferrous sulfate or ferric pyrophosphate, potassium chloride, sodium chloride, calcium carbonate, magnesium sulfate or magnesium chloride, copper sulfate, sulfuric acid An aqueous solution in which zinc or the like is dissolved is added to form an aqueous phase. To this solution, arachidonic acid / DHA / cholesterol-rich fats and oils and nucleotides are added, mixed with a homomixer, and homogenized with a homogenizer. The obtained emulsion is sterilized, concentrated and spray-dried by a conventional method to prepare a powdered milk. This prepared milk powder is dissolved in warm water, diluted about 6 to 8 times, and prepared.

The composition according to the present invention can be used as the above-mentioned food for infants, as well as pharmaceuticals and foods and drinks for humans or animals, powdered milk, enteral nutrition, health food and drink, feed additives, It can be practically used as various types of compositions such as a culture medium additive for cultured cells.

The amount of the active ingredient may be arbitrarily determined, but may be appropriately determined according to the purpose of use (prevention, health, or treatment), age of the patient, administration method, dosage form, and the like. 00
A range from 01 to 10% is appropriate. However, when taken for the purpose of maintaining health or health over a long period of time, the amount may be smaller than the above range, and the present active ingredient has no safety problem. Even if it is used in large quantities, it may not matter. Actually, a 10-day acute toxicity test using mice
No deaths were observed with oral g / kg administration.

Nucleotides, nucleosides, nucleic acids (RN
A, DNA) or its constituent bases are derived from
There are no restrictions on yeast, bacteria, milk, seafood, animals, plants, and the like.
The method for purifying nucleic acids (RNA, DNA), nucleotides, nucleosides or their constituent bases is also not limited, and those that have not been completely purified may be used. Therefore, as described above, in addition to the purified product, the crude product, the content, etc. can be used freely,
Pastes to liquid or suspensions can be widely used.

When used as a food or beverage type composition, the present active ingredient (the processed product thereof) can be used as it is, or used in combination with other foods or food ingredients, and can be used according to a conventional method as appropriate. . The composition according to the present invention using the present active ingredient may be in the form of a solid (powder, granule or the like), a paste, a liquid or a suspension, but may be a sweetener,
It is suitable to formulate into a health drink using sour agents, vitamins and other components commonly used in the production of drinks.

When used as a pharmaceutical type composition, the active ingredient is administered in various forms. Examples of the administration form include tablets, capsules, granules, powders,
Oral administration using a syrup or the like can be mentioned. These various preparations are commonly used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizing agents, suspending agents, coating agents, and the like, in accordance with the usual methods for the main drug. It can be formulated using known adjuvants. The amount used varies depending on symptoms, age, body weight, administration method, dosage form, and the like.
In the case of intravenous administration per day, 0.1 kg / kg body weight.
01 mg to 1000 mg can be administered, 0.01 mg to 1000 mg can be administered in the case of muscle administration, and 0.5 mg in the case of oral administration.
It is good to administer within the range of -2000 mg, preferably 1 -1000 mg.

According to the present invention, as will be apparent from the following description, for example, the following excellent effects are exerted. (1) When nucleic acids, DHA, AA and cholesterol are fortified, polyunsaturated fatty acids n-3 and n-6 and monounsaturated fatty acids in PC and PE of erythrocyte membrane increase and bind to erythrocyte membrane. The protein content increases. (2) It is confirmed that the addition of nucleic acid increases the DNA content in the small intestinal mucosa. (3) When nucleic acid, DHA, AA, and cholesterol are fortified, ch content, choline-containing phospholipid (P-choline) content, ch / P-chol in liver biological membranes
The ine molar ratio is increased as compared to when only nucleic acid is enriched.

Therefore, the composition according to the present invention has an excellent action such as an action of increasing lipids, proteins, cholesterol and / or nucleic acids, and an action of improving balance in various biological membranes.

In the present invention, lipids include fatty acids, fats,
Glycolipids are included. As fatty acids, various saturated and unsaturated fatty acids are widely included, for example,
Examples thereof include n-3 series polyunsaturated fatty acids such as DHA and EPA, n-6 series polyunsaturated fatty acids such as AA, and monounsaturated fatty acids such as oleic acid. Fats are triglycerides formed by esterifying glycerin with three molecules of fatty acids, and glycerophospholipids (glycerophospholipids) are those in which some of the fatty acids constituting the fat are replaced by phosphoric acid (ester). Then, P-choline, phosphatidylcholine (P
C) and phosphatidylethanolamine (PE).

The composition according to the present invention exerts various excellent effects on biological membranes. Specific examples of compounding enhancement of each active ingredient include the following. Cytidine monophosphate 5 to 10 mg, uridine monophosphate 2 to 4 mg, adenosine monophosphate 0 to 4 m in 100 g of powder
g, guanosine-monophosphate 1-3 mg and / or inosine-monophosphate 2-4 mg, and arachidonic acid in powder 1
4.9-60 mg / 00g, 24.5-2 DHA
A composition comprising an edible oil and fat containing 50 mg and 56 to 90 mg of cholesterol.

The following composition is also one of the preferred examples. Cytidine-monophosphoric acid 5 to 10 per 100 g of powder
mg, uridine-monophosphate 2-4 mg, adenosine-
Monophosphoric acid 0-4 mg, guanosine-monophosphoric acid 1-3
and a nucleotide mixture consisting of 2-4 mg of inosine-monophosphoric acid and edible oil containing 4.9-60 mg of arachidonic acid, 24.5-250 mg of DHA and 56-90 mg of cholesterol per 100 g of powder. Composition.

Hereinafter, embodiments of the present invention will be described.

[0032]

Example 1 The effect of the fortification of nucleic acid-related substances on growth and lipid metabolism was examined as follows.

(1) A 3-week-old rat was used as a control group (I)
HA, AA, cholesterol-enhanced group (II), nucleic acid-enhanced group (III) and nucleic acid, DHA, AA, cholesterol-enhanced group (IV) were divided into four groups, and each group was bred for 3 weeks by 6 animals. In the feeds of groups III and IV, nucleotides are added, the amount of which is close to the content, type and ratio of nucleotides in human milk. In group II and group IV feeds, DHA,
AA and cholesterol were added (Table 1). In the table, Control represents a control, AA represents arachidonic acid, DHA represents docosahexaenoic acid, ch represents cholesterol, and N represents nucleotide.

[0034]

[Table 1]

In the following, cholesterol, choline-containing phospholipids and glycogen were measured by an enzymatic method, and fatty acids were measured by gas chromatography. The obtained results are shown in Tables 2 and 3 below. In addition, each numerical value shows the average value of the percentage of the total fatty acid (± SD, n =
6). * P <0.05, ** P <0.01, *** P <
0.001.

[0036]

[Table 2]

[0037]

[Table 3]

As is clear from the above results, the fatty acid composition of phosphatidylcholine (PC) in the erythrocyte membrane was
18: 1, 18: 2 n-6, 20: 4 n- in group IV
6,22: 5 n-3 was higher than the other three groups. 22: 6 n-3 in group IV showed a higher tendency compared to the other three groups, but the difference was not significant. Regarding the fatty acid composition of the phosphatidylethanolamine (PE) of the erythrocyte membrane, the IV group of 18: 1, 18: 2 n-6,
18: 3 n-3, 20: 4 n-6, 20: 5 n-
3,22: 5 n-3 was significantly higher than the other three groups.

FIG. 1 shows the percentage of unsaturated fatty acids in the erythrocyte membrane (in the figure, monounsa indicates monounsaturated fatty acids and PUFA indicates polyunsaturated fatty acids). As is clear from these results, the monounsaturated fatty acids and the polyunsaturated fatty acids n-3 and n-6 in the erythrocyte membranes PC and PE of group IV were significantly increased as compared with the other three groups. Simultaneous fortification of nucleic acid and DHA, AA and cholesterol increases polyunsaturated fatty acids n-3 and n-6 and monounsaturated fatty acids in PC and PE of erythrocyte membrane, and synthesizes polyunsaturated fatty acids and fatty acids It has been fully suggested that the desaturation effect is promoted.

Nucleotides in the erythrocyte membrane, DHA,
FIG. 2 shows the effect of adding AA and cholesterol. As is clear from these results, regarding the lipid composition of the erythrocyte membrane,
Ch and P-ch per protein in erythrocyte membrane of group II
The content of oleine was significantly higher than the group III and group IV. The ch / P-choline molar ratio of the erythrocyte membrane showed no significant difference among the four groups. The protein / lipid in the erythrocyte membrane of group IV was significantly higher than that of groups I and II. It was considered that the simultaneous enhancement of nucleic acid and DHA, AA, and cholesterol increased the content of the protein bound to the erythrocyte membrane and promoted the synthesis of the protein.

(2) For rats in groups (I) to (IV), the RNA and DNA content in the small intestinal mucosa was determined by STS.
Was analyzed by the method. FIG. 3 shows the obtained results. As is clear from these results, in the small intestine, the RNA content of Group IV tended to be higher than that of the other three groups, but the difference was not significant. The DNA content in the small intestinal mucosa of Group III and Group IV was significantly higher than that of Group I.
It was confirmed that the addition of nucleic acid promoted the synthesis of small intestinal mucosal DNA.

(3) The fluidity of the small intestinal microvillus membrane (MVM) was analyzed by the fluorescence depolarization method for the rats in the groups (I) to (IV). FIG. 4 shows the obtained results. As is clear from the results, the anisotropy r value of the film is an index indicating the fluidity of the film, and a lower value indicates that the fluidity increases. The anisotropy r values at 15, 25, and 37 ° C in the small intestinal microvillus membranes of the groups II and IV were significantly lower than those of the group III, indicating that the fluidity of the small intestinal microvillus membranes in both groups was increased. Was. Small intestinal microvillus in groups II and IV
The ch / P-choline molar ratio in the s film was significantly lower than that in group III. It was found that the anisotropy r value of the small intestinal microvillus membrane changed with a tendency similar to the ch / P-choline molar ratio of the membrane. Nucleic acid and DHA, AA enhancement is small intestinal microvil
The effect on the lipid composition and fluidity of lus membrane was given.

(4) For rats in groups (I) to (IV), RNA, DNA, protein, cholesterol (ch), and choline-containing phosphate (P-cholin) in the liver
e) Glycogen was measured. The results obtained are shown in Table 4 below. In addition, each numerical value shows an average value ± SD (n = 6 in each group, which is significantly different from the control group, * P <0.0
5). As is clear from the results, regarding the composition of the liver, the contents of RNA, ch, and P-choline in the liver of Group I were higher than those of the other three groups.

[0044]

[Table 4]

(5) With respect to the rats in the groups (I) to (IV), the respective compositions of the liver mitochondrial membrane and microsomal membrane were analyzed. The results obtained are shown in FIG. As is evident from these results, liver mitochon in groups II and IV
The contents of ch and P-choline per protein in the dria membrane were significantly higher than those in group III. The ch content per protein in the liver microsome membrane of group IV was significantly higher than that of group III. Liver mitochon of group IV
The ch / P-choline molar ratio in dria and microsome membrane is
The value was significantly higher than in group III.

It was suggested that when only nucleic acid was fortified, lipid content in whole liver, lipid content per protein in liver biomembrane and ch / P-choline molar ratio were reduced. When co-enhancing nucleic acids with DHA, AA and cholesterol, the lipid content in whole liver was reduced. But,
Lipid content and ch / P-choline molar ratio in biological membranes increased. It was thought that co-enhancement of nucleic acid and DHA, AA and cholesterol had different effects on lipid content in liver biomembranes and lipid content in tissues other than liver biomembranes.

[0047]

Example 2 Arachidonic acid 4.9 mg, DHA 24.5 mg, cholesterol 5 per 100 g of product powder
6.0 mg, CMP 6.01 mg, UMP
3.85 mg, AMP 0.21 mg, GMP 1.5
25 g of raw material refined fish oil of a commercially available infant formula was fortified so as to be 5 mg and 3.07 mg of IMP to prepare a fortified fish oil. 80 g of skim milk, 4 g of casein, 18 g of whey protein, 40 g of carbohydrates, 0.7 g of minerals, 0.4 g of vitamins.
After adding and mixing 7 g, adjusting the pH, sterilizing and concentrating the solution,
25 g of the above-mentioned fortified fish oil was mixed as a fat and oil, and after homogenization, spray-dried to obtain a dried product. After homogenization, a liquid product was prepared without spray drying.

[0048]

Effect of the Invention By administering the nutritional composition according to the present invention, lipids, proteins, ch, R
The effect of increasing the content of NA and DNA and improving the balance is exerted. Therefore, according to the present invention, the growth of infants, particularly the growth in the weaning period, is promoted, and the maintenance of the health and nutrition of humans and animals is effectively performed.

[Brief description of the drawings]

FIG. 1 shows the amount of unsaturated fatty acids in the erythrocyte membrane.

FIG. 2. Nucleotides, DHA, A in erythrocyte membrane.
The effect of adding A and ch is shown.

FIG. 3 shows the amounts of RNA and DNA in the small intestinal mucosa.

FIG. 4 shows the flowability of small intestinal microvillus membrane.

FIG. 5. Nucleotides, DHA, AA,
The effect of adding ch is shown.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁶ Identification code Agency reference number FI Technical indication location C07H 21/00 A23D 9/00 516 (72) Inventor Yu Kuwata 1-21- Sakaemachi, Higashimurayama-shi, Tokyo 3 Meiji Dairies Co., Ltd.

Claims (11)

[Claims] 1. A nutritional composition having an effect of increasing lipid, protein, cholesterol and / or nucleic acid in a biological membrane, comprising a nucleic acid, DHA, arachidonic acid and cholesterol as active ingredients. 2. The nutritional composition according to claim 1, wherein the nucleic acid is one or more selected from nucleotides, nucleosides, nucleic acids (DNA, RNA), and bases that are constituents thereof. . 3. 100 g of powder, 5-10 mg of cytidine-monophosphate, 2-4 mg of uridine-monophosphate, 0-4 mg of adenosine-monophosphate, 1-3 mg of guanosine-monophosphate and / or 2-3 mg of inosine-monophosphate. 4m
g and arachidonic acid at 4.9 to 60 per 100 g of powder.
lipid, protein, cholesterol and / or edible oil containing 24.5-250 mg of DHA and 56-90 mg of cholesterol.
Or a nutritional composition having a nucleic acid increasing effect. 4. A method for preparing 5 to 10 mg of cytidine-monophosphate, 2 to 4 mg of uridine-monophosphate, 0 to 4 mg of adenosine-monophosphate, 1 to 3 mg of guanosine-monophosphate and 2 to 4 mg of inosine-monophosphate in 100 g of powder. Nucleoside mixture and arachidonic acid in powder 100
4.9-60 mg / g, 24.5-250 DHA
lipid and protein, characterized by comprising an edible oil and fat containing 56 to 90 mg of cholesterol.
A nutritional composition having a cholesterol and / or nucleic acid increasing effect. 5. The nutritional composition according to claim 3, wherein the edible oil or fat contains fish oil. 6. The nutritional composition according to claim 1, wherein the lipid is a fatty acid and / or glycerophospholipid. 7. The method according to claim 1, wherein the fatty acid is a mono- and / or polyunsaturated fatty acid, and the glycerophospholipid is a choline-containing phospholipid, phosphatidylcholine (PC) and / or phosphatidylethanolamine (PE). Item 7. The nutritional composition according to Item 6. 8. The method according to claim 1, wherein the active ingredient is a purified product, a crude product, and / or
Or a substance contained therein.
The nutritional composition according to any one of the above. 9. The composition according to claim 1, wherein the composition is for humans and / or animals.
The nutritional composition according to any one of claims 1 to 8, wherein the composition is a pharmaceutical type and / or a food / beverage type composition. 10. The nutritional composition according to claim 9, wherein the composition is an infant food. 11. The nutritional composition according to claim 10, wherein the infant food is an infant formula.